Anthony A Lombardo Net Worth

The estimated Net Worth of Anthony A Lombardo is at least $2.03 millier dollars as of 2 February 2018. Anthony Lombardo owns over 32 units of Ayala Pharmaceuticals stock worth over $1,858 and over the last 7 years Anthony sold ADXS stock worth over $170.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anthony Lombardo ADXS stock SEC Form 4 insiders trading

Anthony has made over 2 trades of the Ayala Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Anthony sold 32 units of ADXS stock worth $94 on 2 February 2018.

The largest trade Anthony's ever made was selling 32 units of Ayala Pharmaceuticals stock on 2 February 2018 worth over $94. On average, Anthony trades about 14 units every 24 days since 2017. As of 2 February 2018 Anthony still owns at least 92,903 units of Ayala Pharmaceuticals stock.

You can see the complete history of Anthony Lombardo stock trades at the bottom of the page.

What's Anthony Lombardo's mailing address?

Anthony's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON,, NJ, 08540.

Insiders trading at Ayala Pharmaceuticals

Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... et Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.

What does Ayala Pharmaceuticals do?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Complete history of Anthony Lombardo stock trades at Ayala Pharmaceuticals

Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kenneth A. Berlin J.D.,
  Pres, Interim CFO, CEO & Director
• Kenneth Berlin,
  President, Chief Executive Officer, Interim Chief Financial Officer, Director
• Andres Gutierrez,
  Chief Medical Officer and Executive Vice President
• Dr. Andres A. Gutierrez M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Roni Appel,
  Independent Director
• David Sidransky,
  Independent Chairman of the Board
• James Patton,
  Independent Non-Executive Vice Chairman of the Board
• Tim McCarthy,
  Investor Relations
• Samir Khleif,
  Independent Director
• Richard Berman,
  Independent Director
• Igor Gitelman CPA, CPA, M.B.A., MBA,
  Chief Accounting Officer & VP of Fin.
• Gregory T. Mayes,,
  Chief Operating Officer
• Robert J. Spiegel,
  Director
• Robert Petit,
  Chief Scientific Officer
• Sara Bonstein,
  Chief Financial Officer
• Thomas J Mckearn,
  Director
• Thomas J Ridge,
  Director
• Murray A Goldberg,
  Director
• Biotech Fund I, L.P.Israel ...,
  
• Capital Partners Gp, L.L.C....,
  
• Anthony A Lombardo,
  Interim CEO
• Molly Henderson,
  Executive Vice President & CFO
• Fredrick D Cobb,
  Vice President Finance
• John F Rothman,
  VP of Clinical Development
• David J Mauro,
  Chief Medical Officer
• Daniel J. O'connor,
  SVP, Legal & Business Dev Off
• Thomas A Moore,
  Director
• Christy Lee French,
  Exec. Dir. of Medical Affairs
• Mark J Rosenblum,
  Chief Financial Officer
• Biotech Fund I, L.P.Israel ...,
  
• Growth Fund Limited Partner...,
  10% owner
• Vered Bisker Leib,
  Director